"Global Viral Vaccines Market Overview:
Global Viral Vaccines Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Viral Vaccines Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Viral Vaccines involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Viral Vaccines Market:
The Viral Vaccines Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Viral Vaccines Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Viral Vaccines Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Viral Vaccines market has been segmented into:
Recombinant & conjugate vaccines
Inactivated vaccines
By Application, Viral Vaccines market has been segmented into:
Pneumococcal disease
Meningococcal disease
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Viral Vaccines market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Viral Vaccines market.
Top Key Players Covered in Viral Vaccines market are:
Pfizer
Sanofi
GSK
Merck & Co.
AstraZeneca plc
Serum institute of India Private Limited
Moderna
Novartis
among others.
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Viral Vaccines Market by Type
4.1 Viral Vaccines Market Snapshot and Growth Engine
4.2 Viral Vaccines Market Overview
4.3 Recombinant & conjugate vaccines
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Recombinant & conjugate vaccines: Geographic Segmentation Analysis
4.4 Inactivated vaccines
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Inactivated vaccines: Geographic Segmentation Analysis
Chapter 5: Viral Vaccines Market by Application
5.1 Viral Vaccines Market Snapshot and Growth Engine
5.2 Viral Vaccines Market Overview
5.3 Pneumococcal disease
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Pneumococcal disease: Geographic Segmentation Analysis
5.4 Meningococcal disease
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Meningococcal disease: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Viral Vaccines Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 PFIZER
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 SANOFI
6.4 GSK
6.5 MERCK & CO.
6.6 ASTRAZENECA PLC
6.7 SERUM INSTITUTE OF INDIA PRIVATE LIMITED
6.8 MODERNA
6.9 NOVARTIS
6.10 AND AMONG OTHERS.
Chapter 7: Global Viral Vaccines Market By Region
7.1 Overview
7.2. North America Viral Vaccines Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Recombinant & conjugate vaccines
7.2.4.2 Inactivated vaccines
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Pneumococcal disease
7.2.5.2 Meningococcal disease
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Viral Vaccines Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Recombinant & conjugate vaccines
7.3.4.2 Inactivated vaccines
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Pneumococcal disease
7.3.5.2 Meningococcal disease
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Viral Vaccines Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Recombinant & conjugate vaccines
7.4.4.2 Inactivated vaccines
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Pneumococcal disease
7.4.5.2 Meningococcal disease
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Viral Vaccines Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Recombinant & conjugate vaccines
7.5.4.2 Inactivated vaccines
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Pneumococcal disease
7.5.5.2 Meningococcal disease
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Viral Vaccines Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Recombinant & conjugate vaccines
7.6.4.2 Inactivated vaccines
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Pneumococcal disease
7.6.5.2 Meningococcal disease
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Viral Vaccines Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Recombinant & conjugate vaccines
7.7.4.2 Inactivated vaccines
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Pneumococcal disease
7.7.5.2 Meningococcal disease
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Viral Vaccines Scope:
|
Report Data
|
Viral Vaccines Market
|
|
Viral Vaccines Market Size in 2025
|
USD XX million
|
|
Viral Vaccines CAGR 2025 - 2032
|
XX%
|
|
Viral Vaccines Base Year
|
2024
|
|
Viral Vaccines Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Pfizer, Sanofi, GSK, Merck & Co., AstraZeneca plc, Serum institute of India Private Limited, Moderna, Novartis, and among others..
|
|
Key Segments
|
By Type
Recombinant & conjugate vaccines
Inactivated vaccines
By Applications
Pneumococcal disease
Meningococcal disease
|
